DEA Extends Covid-19 Telehealth Prescribing Flexibilities for Another Year.
The Drug Enforcement Administration (DEA) in concert with the Department of Health and Human Services (HHS) is issuing a third extension of telemedicine flexibilities for the prescribing of controlled medications, through December 31, 2025. A DEA-registered practitioner can prescribe a schedule II-V controlled substance to a patient using telemedicine without the need for an in-person medical evaluation, as long as the prescription(s) are for a legitimate medical need, and within the course and scope of the prescriber’s medical practice. As you may recall, the DEA extended the COVID flexibilities through 2024 while it worked on a revised set of rules, which were to...
DEA Extends COVID Telemedicine Prescribing Rules for Controlled Substances
UPDATE: DEA and HHS Extend Telemedicine Flexibilities through 2024 October 9, 2023 Statement from the DEA on Telemedicine Flexibilities deadline: "We continue to carefully consider the input received and are working to promulgate a final set of telemedicine regulations by the fall of 2024, giving patients and medical practitioners time to plan for, and adapt to, the new rules once issued. Accordingly, DEA, jointly with the Department of Health and Human Services (HHS), has extended current telemedicine flexibilities through December 31, 2024. The full text of the extension, entitled “Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled...
DEA Announces Proposed Telemedicine Rule Change for Controlled Substances
On 2/24/23 the U.S. Drug Enforcement Agency (DEA) announced a proposal for permanent rule changes to the Ryan Haight Act that will allow for the prescription of controlled substances through telemedicine, under certain circumstances, after the federal COVID-19 Public Health Emergency (PHE) expires on May 11, 2023. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires prescribers conduct an in-person examination to evaluate each patient at least once before prescribing a controlled substance, even if a patient has already been taking the medication in question. During the PHE, the in-person requirement was changed to allow prescribers to perform...
As of October 2, 2018, all providers practicing in California must check the Controlled Substance Utilization Review and Evaluation System (CURES) database before prescribing certain medications, including opioid pain medications. Physicians and advanced practice providers who prescribe controlled substances already must be registered with CURES 2.0, according to state law. California Health and Safety Code Section 11165.1 requires health care practitioners authorized to prescribe, order, administer, furnish, or dispense scheduled controlled substances to submit a CURES registration application to the Department of Justice before July 1, 2016, or upon receipt of a DEA registration. Senate Bill 482, which was signed...
Hawai’i Providers: Mandatory Opioid Prescription Requirements under Act 66
MIEC’s member providers in Hawai'i who prescribe opioid pain medications should be aware of a new state law which just went into effect this month. This new law imposes more stringent requirements around chronic pain management, patients who are also taking anti-anxiety medication, and/or patient who are on large dosages of opioids. Specific elements of the law are discussed below. Under Hawai'i Act 66 (17), Relating to Heath, as of July 1, 2018, all providers authorized to prescribe opioids in Hawai'i must adopt a written policy that includes the execution of a written informed consent document when prescribing opioids to...
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.